Hill-Rom (NYSE:HRC) Issues Q4 Earnings Guidance

Hill-Rom (NYSE:HRC) issued an update on its fourth quarter earnings guidance on Friday morning. The company provided EPS guidance of $1.64-1.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67. Hill-Rom also updated its FY 2019 guidance to $5.03-5.05 EPS.

Shares of NYSE HRC traded down $4.04 during trading on Friday, reaching $103.92. 694,227 shares of the company traded hands, compared to its average volume of 324,414. The company has a debt-to-equity ratio of 1.10, a quick ratio of 1.27 and a current ratio of 1.69. Hill-Rom has a 12-month low of $81.82 and a 12-month high of $109.18. The company has a fifty day moving average price of $105.40. The firm has a market cap of $7.21 billion, a PE ratio of 21.88, a P/E/G ratio of 1.86 and a beta of 0.90.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.21 by $0.02. Hill-Rom had a return on equity of 21.30% and a net margin of 7.93%. The firm had revenue of $726.80 million during the quarter, compared to analyst estimates of $718.08 million. During the same quarter in the previous year, the business earned $1.15 EPS. Hill-Rom’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, equities analysts expect that Hill-Rom will post 5.04 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Friday, September 20th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Thursday, September 19th. This represents a $0.84 annualized dividend and a dividend yield of 0.81%. Hill-Rom’s dividend payout ratio is presently 17.68%.

Several equities analysts recently weighed in on the company. Barclays lifted their price target on Hill-Rom from $103.00 to $108.00 and gave the company an equal weight rating in a research note on Monday, April 15th. Zacks Investment Research upgraded Hill-Rom from a hold rating to a buy rating and set a $103.00 price target for the company in a research note on Thursday, June 6th. Finally, ValuEngine lowered Hill-Rom from a buy rating to a hold rating in a research note on Thursday. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $107.50.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

See Also: What Are Cryptocurrencies?

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.